Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E23.01 EPS (ttm)1.45 Insider Own0.10% Shs Outstand6.16B Perf Week-1.91%
Market Cap205.48B Forward P/E14.30 EPS next Y2.33 Insider Trans-6.92% Shs Float6.15B Perf Month-3.02%
Income9.20B PEG7.28 EPS next Q0.51 Inst Own74.80% Short Float1.20% Perf Quarter-2.13%
Sales49.12B P/S4.18 EPS this Y-14.50% Inst Trans1.53% Short Ratio3.11 Perf Half Y8.97%
Book/sh10.85 P/B3.08 EPS next Y14.52% ROA6.80% Target Price37.94 Perf Year13.73%
Cash/sh4.50 P/C7.42 EPS next 5Y3.16% ROE15.70% 52W Range26.81 - 35.24 Perf YTD8.97%
Dividend1.12 P/FCF32.13 EPS past 5Y3.10% ROI8.90% 52W High-5.30% Beta0.73
Dividend %3.36% Quick Ratio2.20 Sales past 5Y0.10% Gross Margin81.00% 52W Low24.45% ATR0.44
Employees78300 Current Ratio2.40 Sales Q/Q-4.30% Oper. Margin28.50% RSI (14)37.10 Volatility1.80% 1.15%
OptionableYes Debt/Eq0.53 EPS Q/Q8.60% Profit Margin23.40% Rel Volume0.95 Prev Close33.69
ShortableYes LT Debt/Eq0.44 EarningsJul 28 BMO Payout57.90% Avg Volume23.72M Price33.37
Recom2.30 SMA20-2.10% SMA50-2.24% SMA2003.79% Volume22,624,049 Change-0.95%
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Nov-01-11Downgrade Standpoint Research Buy → Hold
Oct-07-11Initiated MKM Partners Buy $20.50
Sep-14-11Downgrade Barclays Capital Overweight → Equal Weight $21 → $19
Aug-10-11Upgrade Argus Hold → Buy $21
Aug-05-11Upgrade Standpoint Research Hold → Buy $21
Mar-14-11Downgrade Standpoint Research Buy → Hold
Nov-03-10Downgrade Argus Buy → Hold
May-21-10Initiated Jefferies Buy $17.80
Jul-03-15 11:33AM  Hospira wins French biosimilar drug tender at 45 pct discount
Jul-02-15 08:04PM  PRESS DIGEST- British Business - July 3 Reuters
05:57PM  1 Way Pfizer Continues to Stand Out From the Crowd at Motley Fool
04:30PM  Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets Business Wire
10:42AM  5 U.S. Large-Caps Facing Declining Revenue
09:51AM  Icagen, acquired by Pfizer in 2011, turns next chapter at
09:32AM  Icagen Re-launched Through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D
09:30AM  Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D PR Newswire
03:00AM  ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries PR Newswire
Jul-01-15 08:14AM  [video]U.S. Companies Look to the U.K. for Investment Opportunites at TheStreet
Jun-30-15 06:36PM  U.S. doctors, hospitals reap $6.5 bln from drug and device makers -report Reuters
05:31PM  Big pharma to be grilled on tax avoidance AAP
09:10AM  Roche's Multiple Sclerosis Studies Meet Primary Endpoint - Analyst Blog
Jun-29-15 03:53PM  Why Jazz Pharmaceuticals Is Winning
01:52PM  Bank controls add to headaches for Greece's pharmacists Reuters
12:40PM  Dow falls 225 points, in the red for the year amid Greece; VIX spikes 24% at CNBC
Jun-26-15 04:45PM  Zoetis Loses All Of Thursday's Spike On Valeant Buzz at Investor's Business Daily
11:35AM  Is Big Pharma Advertising Getting Out of Control? at 24/7 Wall St.
07:38AM  Valeant Pharmaceuticals And Zoetis: A True Mega Deal Is On The Horizon at Forbes
Jun-25-15 04:35PM  Glaxo, Pfizer Meningitis B Vaccines Get ACIP's Category B - Analyst Blog
04:24PM  Zoetis Shares Surge After Report of Takeover Approach by Valeant at Bloomberg
11:20AM  Joseph J. Echevarria Elected To Pfizers Board Of Directors Business Wire
11:15AM  Pfizer Declares 28-Cent Third-Quarter 2015 Dividend Business Wire
10:21AM  Lilly Blooms; Shares Up 4.5% on Patent Win, Merrill Upgrade at
08:10AM  Short Sellers Become More Focused on Big Pharma at 24/7 Wall St.
Jun-24-15 04:30PM  America's top states for innovation in 2015 at CNBC
03:24PM  U.S. CDC updates recommendation for new meningitis B vaccines Reuters
03:24PM  Pfizer (PFE) Stock Falling on Study Possibly Linking Viagra to Melanoma at TheStreet
01:46PM  Traders see money in this drug stock at CNBC
01:40PM  Paul Tudor Jones' Top Three Stocks Deliver Positive Returns Gurufocus
01:19PM  CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA® for Adolescents and Young Adults 16 through 23 Years of Age Business Wire
01:00PM  Pfizer Starts Phase III Rivipansel Study, GlycoMimetics Up - Analyst Blog
11:37AM  Viagra May Not Cause Melanoma, but the 'Viagra Lifestyle' May be a Problem at The Wall Street Journal
Jun-23-15 04:40PM  Pfizer to Buy Two Meningitis Vaccines from Glaxo for $130M - Analyst Blog
04:35PM  Portola, Bristol-Myers and Pfizer Report Encouraging Data - Analyst Blog
03:51PM  GSK Vaccinates Pfizer to Gain Novartis - Video Blog
02:00PM  Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease Business Wire
11:00AM  Report: Viagra Doesn't Cause Melanoma But The Viagra Lifestyle Might at Forbes
10:00AM  Pfizer Invites Public To View And Listen To Webcast Of July 28 Conference Call With Analysts Business Wire
09:00AM  How Apple, Google and 7 Other Cash-Hoarding Companies Will Spend Their Billions at TheStreet
08:00AM  New Online Community, Quitters Circle, Helps Smokers Trade Cigarettes for Real-Time Support Business Wire
Jun-22-15 05:41PM  Pfizer to buy two vaccines from Glaxo AAP
09:42AM  Pfizer (PFE) Stock Gains Following Purchase of Meningitis Vaccines From GlaxoSmithKline at TheStreet
08:45AM  Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Eliquis (apixaba GlobeNewswire
08:35AM  Pfizer to Acquire Two Meningitis Vaccines at The Wall Street Journal
07:47AM  Early movers: CI, WMB, PFE, ALL, AAPL & more at CNBC
07:45AM  GSK sells two vaccines to Pfizer to ease competition concerns Reuters
07:00AM  Pfizer Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline Business Wire
Jun-21-15 01:35PM  Billionaire Asness Secret Formula Points To Apple, Microsoft, and Pfizer at Insider Monkey
Jun-20-15 12:18AM  Scoring With Blue Chips at
Jun-19-15 08:05PM  3 Reasons Pfizer Stock Could Rise at Investopedia
05:35PM  Paul Tudor Jones Buys Stakes in ADP and Visa
09:02AM  US Economic Growth: What a Difference a Quarter Can Make!
Jun-18-15 09:10AM  Apple and 10 Big Companies That Hoard the Most Cash at TheStreet
08:24AM  Slow Sales Uptake For Brintellix Show The Challenges Facing New Depression Drugs at Forbes
Jun-17-15 12:21PM  Why Bristol-Myers Squibb Could Fall Nearly 10% at
07:08AM  Coverage initiated on Pfizer by Piper Jaffray
Jun-15-15 12:49PM  Notable option activity in equities
08:00AM  Pfizer Consumer Healthcare To Expand Caltrate And Centrum Production In China Business Wire
06:00AM  Dollar's rampage costs companies billions: Study at CNBC
Jun-12-15 06:15PM  3 Reasons Pfizer Stock Could Fall at Investopedia
03:18PM  Bets ahead of experimental Alzheimer's drug
11:23AM  Is Excitement Over Eli Lilly's Alzheimer's Drug Overdone? at
09:30AM  Pfizer's Pristiq Fails in First Phase III Pediatric Study - Analyst Blog
08:52AM  Pharmalot.. Pharmalittle.. As the Weekend Nears: We're Catching up on Pfizer, CEO Pay and Lots More!! at The Wall Street Journal
Jun-11-15 06:57PM  Cramer: Massive biotech moves that make sense at CNBC
03:58PM  Pfizer Trial of Antidepressant Fails to Meet Goal at The Wall Street Journal
03:18PM  U.S. jury clears Pfizer in second trial alleging Zoloft birth defects Reuters
03:00PM  Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder Business Wire
01:43PM  U.S. jury clears Pfizer in second trial over Zoloft
01:33PM  Pfizer Wins Trial Over Claims Zoloft Caused Birth Defects at Bloomberg
Jun-10-15 02:38PM  Top AstraZeneca R&D Exec Leaves to Run a Private Drugmaker at The Wall Street Journal
02:00PM  AstraZeneca Research Executive Morrison Is Leaving Company at The Wall Street Journal
12:18PM  AstraZeneca R&D boss Morrison leaves to head private drugmaker
11:30AM  Today's Top 5 Stock Picks: Diamonds in the Rough at
11:05AM  AstraZeneca research head Morrison leaves to head biotech firm
10:06AM  How to Trade the Stocks of Four Giants in the Health Care Industry at TheStreet
08:30AM  Short Sellers Back Off Big Pharma at 24/7 Wall St.
08:00AM  Pfizer Builds Upon Robust Body Of Knowledge For XELJANZ® (tofacitinib citrate) With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress (EULAR 2015) Business Wire
Jun-08-15 04:43PM  10 drugs to hit fed budget by $50B over decade at CNBC
04:33PM  Pfizer Report Warns of Possible Zoloft and Birth Defect Link
02:01PM  Pfizer Report Discloses Potential Zoloft and Birth Defect Link at Bloomberg
01:00PM  Autoimmune Drugs to Drive Big Pharma Higher in Coming Years at 24/7 Wall St.
11:00AM  Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology Business Wire
10:28AM  FDA weighs best patient group for Amgen cholesterol drug
07:39AM  Is The 21st Century Cures Act Good Or Bad For The Biopharmaceutical Industry? at Forbes
Jun-07-15 09:40AM  New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels at 24/7 Wall St.
Jun-06-15 05:33AM  FDA Reviews Anti-Cholesterol Drugs at The Wall Street Journal
Jun-05-15 05:16PM  FDA weighs approval of first-in-class cholesterol drug
10:44AM  The Fight Against Cholesterol Heats Up; FDA Panel Considers Drugs from Regeneron, Amgen Next Week at
Jun-04-15 06:31PM  FDA panel backs female libido pill, under safety conditions
11:58AM  2015 Global 2000: The World's Largest Drug And Biotech Companies at Forbes
09:00AM  Get Ready. Get Set. Get Old. Pfizer Challenges Conventional Views of Aging through New Campaign Business Wire
Jun-03-15 12:11PM  Pfizer CEO: The Story Behind Ian Read at Investopedia
10:50AM  S&P 500 Index Futures Trading Sharply Higher
08:33AM  Anne Wojcicki: the freewheeling queen of home DNA testing at Financial Times
07:00AM  MannKind's inhaled insulin drug proves hard for diabetics to get at Los Angeles Times
Jun-02-15 04:00PM  [video]Why Health Care Stocks Will Continue to Lead Market Higher at TheStreet
01:22PM  Top 10 Pfizer Venture Investments at Investopedia
01:08PM  Tests for new cancer drugs not reliable enough, doctors say
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLSON LAURIE JExecutive Vice PresidentJun 11Option Exercise25.8726,000672,62096,113Jun 12 09:26 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Sale34.3926,000894,15570,113Jun 12 09:26 AM
HILL CHARLES HExecutive Vice PresidentMay 29Sale34.9242,8701,497,02069,357Jun 02 04:54 PM
SUSMAN SALLYExecutive Vice PresidentMar 12Sale34.0046,1791,570,086150,899Mar 13 10:39 AM
Dolsten MikaelPresident R&DMar 05Sale34.4658,2982,009,152355,911Mar 06 07:32 PM
READ IAN CChairman & CEOMar 05Sale34.6267,5002,336,7931,408,457Mar 06 07:19 PM
OLSON LAURIE JExecutive Vice PresidentFeb 25Option Exercise17.6921,115373,52481,240Feb 27 06:49 PM
HILL CHARLES HExecutive Vice PresidentFeb 25Option Exercise17.6922,523398,432121,572Feb 27 06:42 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise17.6919,426343,64656,250Feb 27 06:42 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise17.6932,855581,205141,441Feb 27 06:42 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 25Option Exercise17.69101,3511,792,899227,982Feb 27 06:42 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 25Option Exercise17.6923,649418,35188,933Feb 27 06:42 PM
READ IAN CChairman & CEOFeb 25Option Exercise17.69197,0723,486,2041,568,718Feb 27 06:50 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise17.6995,7211,693,304261,233Feb 27 06:56 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise17.6949,364873,249159,673Feb 27 06:56 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Option Exercise26.20104,0002,724,800288,775Feb 17 05:50 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 13Sale34.73104,0003,612,323184,775Feb 17 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 12Sale34.859,000313,66170,252Feb 13 01:50 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.3014,800507,619440,886Feb 12 04:01 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 11Sale34.2380,2002,744,861360,686Feb 12 04:01 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 10Sale33.789,000304,02079,252Feb 11 08:02 PM
LANKLER DOUGLAS MExecutive Vice PresidentDec 31Option Exercise18.1921,413389,502127,673Jan 05 05:17 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerDec 31Option Exercise18.1932,120584,263207,985Jan 05 05:17 PM
HILL CHARLES HExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892126,245Jan 05 05:17 PM
OLSON LAURIE JExecutive Vice PresidentDec 31Option Exercise18.1918,737340,82675,811Jan 05 05:17 PM
YOUNG JOHN DGroup PresidentDec 31Option Exercise18.1926,767486,892128,860Jan 05 05:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 31Option Exercise18.1932,120584,26361,803Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 31Option Exercise18.1926,767486,892107,900Jan 05 05:16 PM
BOURLA ALBERTGroup PresidentDec 31Option Exercise18.1916,060292,131113,177Jan 05 05:16 PM
MADDALUNA ANTHONY JExecutive Vice PresidentDec 08Sale32.006,500208,00082,830Dec 09 10:44 AM
HILL CHARLES HExecutive Vice PresidentNov 10Sale30.188,285250,04199,478Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Option Exercise26.2021,600565,920123,462Nov 10 05:34 PM
DAMELIO FRANK AExecutive Vice PresidentNov 07Sale29.7807454,687Nov 10 05:34 PM
YOUNG JOHN DGroup PresidentNov 07Sale29.8921,600645,548101,862Nov 10 05:34 PM
READ IAN CChairman & CEOOct 30Option Exercise17.0354,585929,5831,465,906Nov 03 06:23 PM
DAMELIO FRANK AExecutive Vice PresidentOct 30Option Exercise17.0365,5021,115,499501,494Nov 03 06:23 PM
READ IAN CChairman & CEOOct 30Sale29.7667,5002,008,8001,358,862Nov 03 06:23 PM
MADDALUNA ANTHONY JExecutive Vice PresidentOct 29Sale29.562,42571,68388,987Oct 30 06:23 PM